<DOC>
	<DOC>NCT01323998</DOC>
	<brief_summary>This retrospective study aims to assess treatment patterns within 1 year of initiating BPH treatment, including 5-alpha-reductase inhibitor (5ARI) monotherapy, alpha-blocker (AB) monotherapy, early combination therapy, and delayed combination therapy. The MarketScan database will be utilized for this study (2000-2008)</brief_summary>
	<brief_title>Benign Prostatic Hypertrophy Treatment Patterns &amp; Outcomes: Marketscan</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<criteria>Male aged 50 years or older a diagnostic claim for BPH at least one prescription claim for a 5ARI or AB in the enrollment period continuous eligibility for 6 months prior to and 12 months after index prescription date diagnosis of prostate or bladder cancer during the study period any prostaterelated surgical procedure within 1 month of the index prescription date prescription claim for finasteride 1 mg for male pattern baldness during the study period</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>enlarged prostate</keyword>
	<keyword>Benign prostatic hyperplasia</keyword>
	<keyword>alpha-blocker</keyword>
	<keyword>5-alpha-reductase inhibitor</keyword>
</DOC>